Pfizer- BioNTech seek permission for emergency use of Covid-19 vaccine in adolescents in US
Washington/IBNS: US drug major Pfizer Inc and its German partner BioNTech SE have sought the permission for emergency use of their vaccine in adolescents aged 12 to 15, according to a Reuters report.
Pfizer Inc and BioNTech stated that they have made a request to the US Food and Drug Administration for the expansion of use of their vaccine which proved to be 90 per cent effective against the novel coronavirus in clinical trials.
In March, the drugmakers said that their vaccine has shown positive results and proven safe among the age group 12 to 15 in a clinical trial.
This could be a big development as drugmakers across the world are still facing the question if the vaccine works and is safe for use in children.
Inoculating children is a major step toward achieving "herd immunity" and controlling the pandemic, according to experts, the report said.
The companies plan to approach other regulatory authorities across the globe for similar permissions.